CY2619B2 - - Google Patents

Info

Publication number
CY2619B2
CY2619B2 CY201200011A CY1200011A CY2619B2 CY 2619 B2 CY2619 B2 CY 2619B2 CY 201200011 A CY201200011 A CY 201200011A CY 1200011 A CY1200011 A CY 1200011A CY 2619 B2 CY2619 B2 CY 2619B2
Authority
CY
Cyprus
Application number
CY201200011A
Other languages
Greek (el)
Inventor
Lars Thim
Birgitte Wulff
Martin Judge
Ole Madsen
Jens Holst
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2619(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of CY2619B2 publication Critical patent/CY2619B2/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CY201200011A 1996-03-01 2012-10-12 CY2619B2 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK23096 1996-03-01
DK23196 1996-03-01
EP08103786A EP1975177B1 (en) 1996-03-01 1997-02-27 An appetite-suppressing peptide, its compositions and use

Publications (1)

Publication Number Publication Date
CY2619B2 true CY2619B2 (cg-RX-API-DMAC10.html) 2013-03-13

Family

ID=26063575

Family Applications (2)

Application Number Title Priority Date Filing Date
CY201200011A CY2619B2 (cg-RX-API-DMAC10.html) 1996-03-01 2012-10-12
CY2013008C CY2013008I2 (el) 1996-03-01 2013-02-27 Πεπτιδιο κατασταλτικο της ορεξης, συνθεσεις και χρηση αυτου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2013008C CY2013008I2 (el) 1996-03-01 2013-02-27 Πεπτιδιο κατασταλτικο της ορεξης, συνθεσεις και χρηση αυτου

Country Status (22)

Country Link
EP (4) EP1231218B1 (cg-RX-API-DMAC10.html)
JP (1) JP4064460B2 (cg-RX-API-DMAC10.html)
KR (1) KR100611130B1 (cg-RX-API-DMAC10.html)
CN (1) CN1112367C (cg-RX-API-DMAC10.html)
AT (3) ATE505485T1 (cg-RX-API-DMAC10.html)
AU (1) AU710818B2 (cg-RX-API-DMAC10.html)
BR (1) BR9707807A (cg-RX-API-DMAC10.html)
CA (1) CA2246733C (cg-RX-API-DMAC10.html)
CY (2) CY2619B2 (cg-RX-API-DMAC10.html)
CZ (1) CZ297338B6 (cg-RX-API-DMAC10.html)
DE (3) DE69740176D1 (cg-RX-API-DMAC10.html)
DK (2) DK1975177T3 (cg-RX-API-DMAC10.html)
ES (3) ES2364705T3 (cg-RX-API-DMAC10.html)
FR (1) FR13C0009I2 (cg-RX-API-DMAC10.html)
HU (1) HU229234B1 (cg-RX-API-DMAC10.html)
IL (1) IL125805A0 (cg-RX-API-DMAC10.html)
NO (2) NO323043B1 (cg-RX-API-DMAC10.html)
PL (1) PL187095B1 (cg-RX-API-DMAC10.html)
PT (1) PT1975177E (cg-RX-API-DMAC10.html)
RU (1) RU2197261C2 (cg-RX-API-DMAC10.html)
UA (1) UA70283C2 (cg-RX-API-DMAC10.html)
WO (1) WO1997031943A1 (cg-RX-API-DMAC10.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
BR9707807A (pt) * 1996-03-01 1999-07-27 Novo Nordisk As Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo
BRPI9708566B8 (pt) 1996-04-12 2022-01-18 Ontario Inc 1149336 análogo de glp-2 de mamífero, e, composição farmacêutica.
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69737916T2 (de) * 1996-11-12 2008-04-03 Novo Nordisk A/S Verwendung von GLP-1 Peptiden
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO1999014239A1 (de) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Glp−1製剤
AU2610599A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
ATE466028T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
ES2484966T3 (es) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
EP1592471B1 (en) 2003-02-04 2011-03-23 Novo Nordisk A/S Injection device with rotatable dose setting mechanism
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド アルブミン融合蛋白質
ES2375802T3 (es) 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
RU2262945C1 (ru) * 2004-04-29 2005-10-27 Закрытое акционерное общество "Научно-производственное предприятие "Тринита" Способ снижения массы тела в эксперименте на животных
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ ノルディスク アクティーゼルスカブ Glp−1アゴニストを用いた薬剤誘発性肥満の中和
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
AU2006242998B2 (en) 2005-05-04 2012-03-22 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
RS51319B (sr) 2005-09-22 2010-12-31 Biocompatibles Uk Limited GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
NZ593017A (en) 2006-08-09 2011-08-26 Intarcia Therapeutics Inc Piston assembly for positioning lumen in an osmotic delivery system having groove to retain elastomeric O-ring
UA102506C2 (ru) 2006-11-08 2013-07-25 Зиланд Фарма А/С Селективные аналоги глюкагоноподобного пептида-2 (glp-2)
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
JP2010536717A (ja) * 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン(mic−1)活性を調節するための作用物質及び方法
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αAL14 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス,インコーポレイティド インプラントの設置及び撤去システム
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP6563614B1 (ja) 2016-12-09 2019-08-21 ジーランド・ファーマ・ア/エス アシル化glp−1/glp−2二重アゴニスト
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス,インコーポレイティド Glp-1受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
EP3881861B1 (en) 2017-06-16 2024-07-31 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
WO2020223761A1 (en) * 2019-05-06 2020-11-12 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
AU6543286A (en) 1985-10-25 1987-05-19 Zymogenetics Inc. Method of using bar1 for secreting foreign proteins
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
ATE170557T1 (de) 1987-07-24 1998-09-15 Chiron Corp Züchtung von insektenzellen mit airlift-reaktoren
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO1990005783A1 (en) 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
BR9707807A (pt) * 1996-03-01 1999-07-27 Novo Nordisk As Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo

Also Published As

Publication number Publication date
FR13C0009I1 (cg-RX-API-DMAC10.html) 2013-03-22
FR13C0009I2 (fr) 2013-08-16
PL187095B1 (pl) 2004-05-31
PL328732A1 (en) 1999-02-15
NO984005D0 (no) 1998-08-31
EP0891378B1 (en) 2002-11-13
ATE505485T1 (de) 2011-04-15
EP1231218A3 (en) 2002-10-30
KR19990087439A (ko) 1999-12-27
ES2364705T3 (es) 2011-09-12
CY2013008I1 (el) 2015-08-05
DE69717092T2 (de) 2003-07-24
EP1975177B1 (en) 2011-04-13
DK1975177T3 (da) 2011-07-25
CN1112367C (zh) 2003-06-25
IL125805A0 (en) 1999-04-11
DK0891378T3 (da) 2003-01-06
UA70283C2 (en) 2004-10-15
EP1231218A2 (en) 2002-08-14
DE69740176D1 (de) 2011-05-26
AU1871597A (en) 1997-09-16
HUP9902670A3 (en) 2000-02-28
CZ273698A3 (cs) 1998-12-16
PT1975177E (pt) 2011-07-26
ATE227737T1 (de) 2002-11-15
RU2197261C2 (ru) 2003-01-27
EP1975177A1 (en) 2008-10-01
EP2295453A2 (en) 2011-03-16
DE69738695D1 (de) 2008-06-26
EP1231218B1 (en) 2008-05-14
JP4064460B2 (ja) 2008-03-19
CA2246733C (en) 2010-07-20
NO323043B1 (no) 2006-12-27
JP2000505460A (ja) 2000-05-09
AU710818B2 (en) 1999-09-30
ATE395359T1 (de) 2008-05-15
KR100611130B1 (ko) 2006-11-30
NO2013006I1 (no) 2013-04-02
EP0891378A1 (en) 1999-01-20
ES2306685T3 (es) 2008-11-16
CN1215405A (zh) 1999-04-28
ES2187756T3 (es) 2003-06-16
CY2013008I2 (el) 2015-08-05
NO984005L (no) 1998-08-31
EP2295453A3 (en) 2011-03-30
BR9707807A (pt) 1999-07-27
NO2013006I2 (cg-RX-API-DMAC10.html) 2013-03-12
CA2246733A1 (en) 1997-09-04
WO1997031943A1 (en) 1997-09-04
DE69717092D1 (de) 2002-12-19
CZ297338B6 (cs) 2006-11-15
HU229234B1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
CY2619B2 (cg-RX-API-DMAC10.html)
AR026662A2 (cg-RX-API-DMAC10.html)
BRPI9713914B8 (cg-RX-API-DMAC10.html)
IN183755B (cg-RX-API-DMAC10.html)
IN187258B (cg-RX-API-DMAC10.html)
IN189985B (cg-RX-API-DMAC10.html)
IN182289B (cg-RX-API-DMAC10.html)
ITCN960005V0 (cg-RX-API-DMAC10.html)
BR9603859A (cg-RX-API-DMAC10.html)
ITMI960486V0 (cg-RX-API-DMAC10.html)
BR7601346U (cg-RX-API-DMAC10.html)
ITMI960561V0 (cg-RX-API-DMAC10.html)
BR7600721U (cg-RX-API-DMAC10.html)
CN3044172S (cg-RX-API-DMAC10.html)
CN3039213S (cg-RX-API-DMAC10.html)
CN3046753S (cg-RX-API-DMAC10.html)
CN3042424S (cg-RX-API-DMAC10.html)
CN3045911S (cg-RX-API-DMAC10.html)
EP0954798A4 (cg-RX-API-DMAC10.html)
CN3045888S (cg-RX-API-DMAC10.html)
CN3045880S (cg-RX-API-DMAC10.html)
CN3042289S (cg-RX-API-DMAC10.html)
CN3042589S (cg-RX-API-DMAC10.html)
CN3045853S (cg-RX-API-DMAC10.html)
CN3045806S (cg-RX-API-DMAC10.html)